Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3443290 | 0.85 | TP53 (0.54) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1704022 | 0.79 | KDR (0.53) | KMT2AMEN1KDR | |
| SCHEMBL12346315 | 0.78 | ALDH1A1 (0.47) | MAPTALDH1A1TDP1KDRHTT | |
| SCHEMBL1702775 | 0.77 | KDR (0.58) | MAPTSMN1; SMN2PKMKDRPDGFRA | |
| SCHEMBL1703240 | 0.77 | KDR (0.45) | MAPTKMT2AMEN1SMN1; SMN2KDR | |
| SCHEMBL3443455 | 0.76 | CNR1 (0.52) | KMT2ASMN1; SMN2PKMKDRPDGFRA | |
| SCHEMBL3442309 | 0.76 | MEN1 (0.57) | MAPTKMT2AMEN1SMN1; SMN2KDR | |
| SCHEMBL3442732 | 0.76 | KDR (0.57) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3442391 | 0.75 | KDR (0.56) | MAPTKMT2AMEN1SMN1; SMN2KDR | |
| SCHEMBL3443775 | 0.74 | KDR (0.50) | MAPTKMT2AMEN1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-1845978-B1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | disclosed |
| EP-2211856-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | The Hospital For Sick Children (CA) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009073564-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-06-11 | — | — | WO | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| EP-1845978-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077319-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | MAPT 3762/4885ALDH1A1 1845/4885KMT2A 3981/4885 |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | MAPT 3762/4885ALDH1A1 1845/4885KMT2A 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.